Evaluation of a digital tool supporting therapeutic decision making for the personalized management of patients with type 2 diabetes not treated with insulin: A pilot study
Authors' conclusion
When performed in a structured manner and used to modify the diabetes therapy through an algorithm-driven digital tool, SMBG can lead to significant improvements of glycemic control and variability in patients with type 2 diabetes not treated with insulin.
Study context
- Population
- Patients with non-insulin-treated T2D and inadequate glucose control; age 64.3 ± 9.4 years, disease duration 13.2 ± 9.1 years, HbA1c 7.8 ± 0.6%completed the study
- Participants
- 82 patients
- Comparison
- Personalized Treatment Tool vs control
- Personalized Treatment Tool (PTT)n = 41
- Controln = 41reference
Methodological detailscluster-randomized, single-center, 16-week
- Cluster-randomized
- Single-center
- 16-week
Primary result
As reported in the abstract
Changes in indicators of glucose control and variability · 16 weeks
- Changes in indicators of glucose control and variability were not statistically different between the two groups
Further findings
Subgroup on a single anti-diabetes drug at baseline: changes in HbA1c, CGM-derived TIR 70-140 mg/dl, 24-hour MSG, GRADE and HBGI · 16 weeks
- Significantly improved with PTT (n=9) vs control (n=14)
Original publication
Evaluation of a digital tool supporting therapeutic decision making for the personalized management of patients with type 2 diabetes not treated with insulin: A pilot study. Diabetes Res Clin Pract. Published 20 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →